MINIMAL RESIDUAL DISEASE
Clinical trials for MINIMAL RESIDUAL DISEASE explained in plain language.
Never miss a new study
Get alerted when new MINIMAL RESIDUAL DISEASE trials appear
Sign up with your email to follow new studies for MINIMAL RESIDUAL DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New stem cell method aims to cut transplant complications in blood cancer patients
Disease control Recruiting nowThis study tests a new way to prepare stem cells for transplant in children and adults with blood cancers like leukemia. The method removes certain immune cells to lower the risk of graft-versus-host disease, a serious side effect. About 70 participants will receive the treatment…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated May 16, 2026 23:50 UTC
-
New cell combo aims to wipe out hidden colorectal cancer cells
Disease control Recruiting nowThis early-phase trial tests a new treatment for colorectal cancer patients who have minimal residual disease (tiny amounts of cancer left after treatment). The therapy uses specially engineered immune cells (TROP2-CAR-NK cells) combined with a targeted drug called cetuximab. The…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 14, 2026 12:04 UTC
-
New combo targets hidden cancer cells in colorectal patients
Disease control Recruiting nowThis study tests whether a combination of two drugs, fruquintinib and tislelizumab, can control colorectal cancer in people who have completed chemotherapy but still have signs of minimal residual disease (MRD) based on a sensitive blood test (ctDNA). About 20 adults with stable …
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:54 UTC
-
Engineered immune cells take aim at returning leukemia
Disease control Recruiting nowThis early-stage study tests a new treatment for children and adults with acute leukemia that has come back or not responded after a donor stem cell transplant. The treatment uses the patient's own immune cells (T cells) that are modified in a lab to recognize and attack a protei…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Massive cancer biobank aims to unlock secrets of the disease
Knowledge-focused Recruiting nowThis study is creating a large collection of blood and tissue samples from 100,000 adults with cancer. The goal is to store these samples and health data for future research to improve cancer detection and treatment. Participants provide consent and samples, but do not receive an…
Matched conditions: MINIMAL RESIDUAL DISEASE
Sponsor: Caris Science, Inc. • Aim: Knowledge-focused
Last updated May 04, 2026 16:18 UTC
-
New blood test could spot lung cancer return months earlier
Knowledge-focused Recruiting nowThis study looks at whether advanced blood tests and artificial intelligence can detect lung cancer coming back after surgery, earlier than standard scans. Researchers will follow 100 people who had lung cancer surgery and chemotherapy. The goal is to create a better monitoring s…
Matched conditions: MINIMAL RESIDUAL DISEASE
Sponsor: Peking University People's Hospital • Aim: Knowledge-focused
Last updated Apr 24, 2026 16:19 UTC